Hemifacial Spasm Market Research Report- Global Forecast till 2027

Hemifacial Spasm Market Research Information: By Diagnosis (Mri, Ct Or Cat Scan, Angiography (Arteriography)), Treatment (Medical Treatment, Surgical Treatment, Combinational Therapy, Tens, Physical Therapy, Others), End User – Global Forecast Till 2027

ID: MRFR/MED/4086-HCR | February 2021 | Region: Global | 85 pages

Please note that the assessment period of report has been updated from 2018-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Scenario:


Hemifacial spasm is a painless neurological condition characterized by persistent or brief involuntary contractions of the muscles innervated by the facial nerve. Vascular compression triggers the primary hemifacial spasm, and secondary hemifacial spasm comprises all other causes of facial nerve damage.


According to the study published in The Scientific World Journal in 2014, it is found that hemifacial spasm is prevalent in 9.8 per 100,000 individuals, and the average age for the onset of hemifacial spasm is 44 years. It is also reported that women and Asian populations have a high susceptibility to hemifacial spasm.


It is noted that increasing technological advancements and growing awareness are the key factors driving the hemifacial spasm market. Nowadays, people are becoming more aware of different types of neurological disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. Thus, increasing awareness has provided a push to the growth of the market.


Various other factors such as increased incidence of craniofacial tremor, and facial chorea, unmet medical needs, increasing government assistance, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement are continuously contributing to the growth of the global hemifacial spasm market.


Despite these drivers, there are some issues associated with hemifacial spasm market. The difficult diagnosis, cost of treatment, side-effects of botulinum toxin, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.


It is estimated that the hemifacial spasm market is expected to grow at a CAGR 7.5% during the forecast period of 2017-2023.


Research Methodology:


 Hemifacial Spasm


Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience:



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities


Segmentation:


The global hemifacial spasm market is segmented on the basis of diagnosis, treatment, and end user.


On the basis of the diagnosis, the market is classified as magnetic resonance imaging (MRI), computed tomography (CT or CAT scan), angiography (Arteriography), and others.


On the basis of the treatment, the market is classified as medical treatment, surgical treatment, combinational therapy, transcutaneous electric nerve stimulation (TENS) therapy, physical therapy, and others. The medical treatment is further classified into Botulinum Neurotoxin (BoNT) Injections and Pharmaceuticals. The sub-segment of Botulinum Neurotoxin (BoNT) Injections includes BoNT-A, BoNT-B, onabotulinumtoxinA, incobotulinumtoxinA, and rimabotulinumtoxinB. The sub-segment of pharmaceuticals include anticonvulsants and GABAergic drugs. The surgical treatment is further classified into microvascular decompression (MVD), and others.


On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.


Regional Analysis:


The Americas dominate the hemifacial spasm market owing to the rising technological advancements and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion, and hospital care accounted for a share of 32.3%.


Europe holds the second position in the hemifacial spasm market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the European market.


The Asia Pacific is the fastest growing hemifacial spasm market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015. An increasing prevalence rate among Asian population is also propelling the growth of the market.


The Middle East & Africa holds the lowest share of the global market due to lack of technical knowledge and poor medical facilities.


Key Players:


Some of key the players in the global hemifacial spasm market are Abbott, Allergan, Inc., Cephalon Inc., GlaxoSmithKline plc, Ipsen Group, Johnson & Johnson Services, Inc., Medytox,Inc., Merz Pharma GmbH and Co. KGaA, Novartis AG, Pfizer, Revance Therapeutics, Inc., ROCHE, Sanofi S.A, Shire plc, Stryker, Sunovion Pharmaceuticals, Inc., UCB S.A., US WorldMeds, LLC., and Valeant Pharmaceuticals International, Inc.



Frequently Asked Questions (FAQ) :


A Hemifacial Spasm Is A Painless Neurological Condition Characterized By Persistent Or Brief Involuntary Contractions Of The Muscles Innervated By The Facial Nerve.

Hemifacial Spasm Market is expected to exhibit a strong 7.5% CAGR over the Forecast Period From 2017 to 2023.

Rising Incidence of Craniofacial Tremors And Increasing Availability Of Reimbursement For Hemifacial Spasm Treatments Are The Major Drivers For The Global Hemifacial Spasm Market.

The Americas are the dominant force in the Global Hemifacial Spasm Market.

Leading Players in the Hemifacial Spasm Market Include Allergan, Abbott, and Cephalon, among others.

Table Of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Hemifacial Spasm Market, By Diagnosis

6.1 Introduction

6.2 Magnetic Resonance Imaging (MRI)

6.2.1 Market Estimates & Forecast, 2020 – 2023

6.3 Computed Tomography (CT Or CAT Scan)

6.3.1 Market Estimates & Forecast, 2020 – 2023

6.4 Angiography (Arteriography)

6.4.1 Market Estimates & Forecast, 2020 – 2023

6.5 Others

6.5.1 Market Estimates & Forecast, 2020 – 2023

Chapter 7. Global Hemifacial Spasm Market, By Treatment

7.1 Introduction

7.2 Medical Treatment

7.2.1 Market Estimates & Forecast, 2020 – 2027

7.3 Surgical Treatment

7.3.1 Market Estimates & Forecast, 2020 – 2027

7.4 Combinational Therapy

7.4.1 Market Estimates & Forecast, 2020 – 2027

7.5 Transcutaneous Electric Nerve Stimulation (TENS) Therapy

7.5.1 Market Estimates & Forecast, 2020 – 2027

7.6 Physical Therapy

7.6.1 Market Estimates & Forecast, 2020 – 2027

7.7 Others

7.7.1 Market Estimates & Forecast, 2020 – 2027

Chapter 8. Global Hemifacial Spasm Market, By End User

8.1 Introduction

8.2 Hospitals

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.3 Clinics

8.3.1 Market Estimates & Forecast, 2020 – 2027

8.4 Diagnostic Centers

8.4.1 Market Estimates & Forecast, 2020 – 2027

8.5 Drug Stores

8.5.1 Market Estimates & Forecast, 2020 – 2027

8.6 Pharmacies

8.6.1 Market Estimates & Forecast, 2020 – 2027

8.7 Others

8.7.1 Market Estimates & Forecast, 2020 – 2027

Chapter 9. Global Hemifacial Spasm Market, By Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest Of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic Of Korea

9.4.6 Rest Of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest Of The Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Abbott Laboratories

11.1.1 Company Overview

11.1.2 Diagnosis Of Causative Agents Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Allergan, Inc.

11.2.1 Company Overview

11.2.2 Diagnosis Of Causative Agents Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Cephalon, Inc.

11.3.1 Company Overview

11.3.2 Diagnosis Of Causative Agents Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 GlaxoSmithKline Plc

11.4.1 Company Overview

11.4.2 Diagnosis Of Causative Agents/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Ipsen Group

11.5.1 Company Overview

11.5.2 Diagnosis Of Causative Agents Overview

11.5.3 Financial Overview

11.5.4 Key Developments

11.6 Johnson & Johnson Services, Inc.

11.6.1 Company Overview

11.6.2 Diagnosis Of Causative Agents Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 MERZ PHARMA GMBH AND CO. KGAA.

11.7.1 Overview

11.7.2 Diagnosis Of Causative Agents Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs Of The Market

12.2 Key Companies To Watch

12.3 Prediction Of Hemifacial Spasm Industry

Chapter 13

Appendix

LIST OF TABLES

Table 1 Hemifacial Spasm Industry Synopsis, 2020 – 2027

Table 2 Hemifacial Spasm Market Estimates And Forecast, 2020 – 2027, (USD Million)

Table 3 Hemifacial Spasm Market By Region, 2020 – 2027, (USD Million)

Table 4 Hemifacial Spasm Market By Diagnosis, 2020 – 2027, (USD Million)

Table 5 Hemifacial Spasm Market By Treatment, 2020 – 2027, (USD Million)

Table 6 Hemifacial Spasm Market By End Users, 2020 – 2027, (USD Million)

Table 7 North America Hemifacial Spasm Market By Diagnosis, 2020 – 2027, (USD Million)

Table 8 North America Hemifacial Spasm Market By Treatment, 2020 – 2027, (USD Million)

Table 9 North America Hemifacial Spasm Market By End Users, 2020 – 2027, (USD Million)

Table 10 US Hemifacial Spasm Market By Diagnosis, 2020 – 2027, (USD Million)

Table 11 US Hemifacial Spasm Market By Treatment, 2020 – 2027, (USD Million)

Table 12 US Hemifacial Spasm Market By End Users, 2020 – 2027, (USD Million)

Table 13 Canada Hemifacial Spasm Market By Diagnosis, 2020 – 2027, (USD Million)

Table 14 Canada Hemifacial Spasm Market By Treatment, 2020 – 2027, (USD Million)

Table 15 Canada Hemifacial Spasm Market By End Users, 2020 – 2027, (USD Million)

Table 16 South America Hemifacial Spasm Market By Diagnosis, 2020 – 2027, (USD Million)

Table 17 South America Hemifacial Spasm Market By Treatment, 2020 – 2027, (USD Million)

Table 18 South America Hemifacial Spasm Market By End Users, 2020 – 2027, (USD Million)

Table 19 Europe Hemifacial Spasm Market By Diagnosis, 2020 – 2027, (USD Million)

Table 20 Europe Hemifacial Spasm Market By Treatment, 2020 – 2027, (USD Million)

Table 21 Europe Hemifacial Spasm Market By End Users, 2020 – 2027, (USD Million)

Table 22 Western Europe Hemifacial Spasm Market By Diagnosis, 2020 – 2027, (USD Million)

Table 23 Western Europe Hemifacial Spasm Market By Treatment, 2020 – 2027, (USD Million)

Table 24 Western Europe Hemifacial Spasm Market By End Users, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Hemifacial Spasm Market By Diagnosis, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Hemifacial Spasm Market By Treatment, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Hemifacial Spasm Market By End Users, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Hemifacial Spasm Market By Diagnosis, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Hemifacial Spasm Market By Treatment, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Hemifacial Spasm Market By End Users, 2020 – 2027, (USD Million)

Table 31 Middle East & Africa Hemifacial Spasm Market By Diagnosis, 2020 – 2027, (USD Million)

Table 32 Middle East & Africa Hemifacial Spasm Market By Treatment, 2020 – 2027, (USD Million)

Table 33 Middle East & Africa Hemifacial Spasm Market By End Users, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation For Hemifacial Spasm Market

Figure 3 Segmentation Market Dynamics For Hemifacial Spasm Market

Figure 4 Global Hemifacial Spasm Market Share, By Diagnosis 2020

Figure 5 Global Hemifacial Spasm Market Share, By Treatment 2020

Figure 6 Global Hemifacial Spasm Market Share, By End Users, 2020

Figure 7 Global Hemifacial Spasm Market Share, By Region, 2020

Figure 8 North America Hemifacial Spasm Market Share, By Country, 2020

Figure 9 Europe Hemifacial Spasm Market Share, By Country, 2020

Figure 10 Asia Pacific Hemifacial Spasm Market Share, By Country, 2020

Figure 11 Middle East & Africa Hemifacial Spasm Market Share, By Country, 2020

Figure 12 Global Hemifacial Spasm Market: Company Share Analysis, 2020 (%)

Figure 13 Abbott Laboratories: Key Financials

Figure 14 Abbott Laboratories: Segmental Revenue

Figure 15 Abbott Laboratories: Geographical Revenue

Figure 16 Allergan, Inc.: Key Financials

Figure 17 Allergan, Inc.: Segmental Revenue

Figure 18 Allergan, Inc.: Geographical Revenue

Figure 19 Cephalon, Inc.: Key Financials

Figure 20 Cephalon, Inc.: Segmental Revenue

Figure 21 Cephalon, Inc.: Geographical Revenue

Figure 22 GlaxoSmithKline Plc: Key Financials

Figure 23 GlaxoSmithKline Plc: Segmental Revenue

Figure 24 GlaxoSmithKline Plc: Geographical Revenue

Figure 25 Ipsen Group: Key Financials

Figure 26 Ipsen Group: Segmental Revenue

Figure 27 Ipsen Group Geographical Revenue

Figure 28 Johnson & Johnson Services, Inc.: Key Financials

Figure 29 Johnson & Johnson Services, Inc.: Segmental Revenue

Figure 30 Johnson & Johnson Services, Inc.: Geographical Revenue

Figure 31 MERZ PHARMA GMBH AND CO. KGAA.: Key Financials

Figure 32 MERZ PHARMA GMBH AND CO. KGAA.: Segmental Revenue

Figure 33 MERZ PHARMA GMBH AND CO. KGAA.: Geographical Revenue